One of the earliest successes in targeted cancer treatment was imatinib, a tyrosine kinase inhibitor that targets the breakpoint cluster region and Abelson murine leukemia (BCR-ABL) fusion protein in chronic myeloid leukemia (CML) [10]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.